VEGFR inhibitors such as sorafenib and lenvatinib have been reported to cause endothelial dysfunction associated with reduced NO production and activation of endothelin-1, a potent vasoconstrictor33–37. The gene discussed is EDN1; the disease is endothelial dysfunction.